Lifordi Immunotherapeutics

What Lifordi Immunotherapeutics does

Lifordi Immunotherapeutics is a clinical-stage biotechnology company developing antibody-drug conjugates (ADCs) for autoimmune and inflammatory disorders. Headquartered in Burlington, Massachusetts, the company was founded in 2023–2024 and is among the first to apply ADC technology—proven in oncology—to immune-mediated diseases. Its lead candidate, LFD-200, is a glucocorticoid ADC engineered to bind VISTA (V-domain Immunoglobulin Suppressor of T-cell Activation), a cell surface protein selectively expressed on myeloid cells, T cells, and plasma B cells. The construct is designed with a short 14-hour serum half-life but extended tissue exposure within immune cells, intended to reduce systemic glucocorticoid toxicity while preserving immunosuppressive efficacy. LFD-200 is administered subcutaneously and is currently in a Phase 1 Multiple Ascending Dose study in patients with moderate-to-severe rheumatoid arthritis across sites in Georgia, Moldova, Poland, and Ukraine, with initial Phase 1 data expected by end of 2026 and presented at EULAR 2026.

The company's underlying technology is a VISTA-targeting ADC delivery platform capable of carrying diverse payloads—including glucocorticoids, antisense oligonucleotides (ASOs), siRNAs, and small molecule inhibitors—to immune cells. This platform underpins Lifordi's pipeline expansion strategy into gastroenterology, pulmonology, and dermatology indications, with an ASO ADC candidate in lead optimization. The company has assembled a leadership team with prior experience at Shire, Amgen, Homology Medicines, Tesaro, and ImmuNext, and is backed by ARCH Venture Partners, 5AM Ventures, Atlas Venture, and Sanofi Ventures, having raised $112 million cumulatively through a $70M Series A and a $42M strategic investment.

Lifordi's business model is a traditional pharmaceutical drug development and commercialization pathway, with revenue expected to be generated through eventual drug commercialization upon regulatory approval under a one-time license model. The company has no disclosed product revenue, no commercial pricing, and currently distributes its therapeutic candidate exclusively through clinical trial sites. Go-to-market relies on scientific conference presentations (ACR, EULAR), peer-reviewed publications, and press relations to engage rheumatologists, healthcare providers, researchers, and pharmaceutical partners. At its current Phase 1 stage, Lifordi is pre-revenue and entirely dependent on equity capital to fund operations and clinical advancement.

Name

Lifordi Immunotherapeutics

Legal name

Lifordi Immunotherapeutics, Inc.

Website

https://lifordi.com

Company type

Private

Founded year

2024

Operating status

Operating

Headcount range

11–50 employees

Short description

Lifordi Immunotherapeutics is a clinical-stage biotech developing antibody-drug conjugates that target VISTA-expressing immune cells to deliver glucocorticoids and other payloads for autoimmune and inflammatory diseases, with lead candidate LFD-200 in Phase 1 trials for rheumatoid arthritis.

Ownership category

akta.pro rank

Product category

Autoimmune Disease Therapeutics

NAICS

Scientific Research and Development Services (5417)

SIC

Services-Misc Health & Allied Services, Nec (8090)

akta.pro primary industry

Antibody-Drug Conjugates (ADCs) & Antibody Conjugates (HLAAAAAE)

akta.pro secondary industries

Immunology & Inflammation Pharmaceuticals (HLAIAAAD), Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)

Keywords

• Antibody-drug conjugates
• Autoimmune therapeutics
• Inflammatory disease treatment
• VISTA targeting platform
• Clinical-stage biopharmaceuticals

Headquarters

HQ city

Burlington

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Drug Development and Commercialization: As a clinical-stage biotech company, Lifordi is developing ADC-based therapeutics for autoimmune and inflammatory disorders. The company is currently in Phase 1 clinical trials for LFD-200 in rheumatoid arthritis. Revenue will be generated through eventual drug commercialization upon regulatory approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Lifordi Immunotherapeutics is a clinical-stage biotech developing antibody-drug conjugates (ADCs) that target VISTA-expressing immune cells to deliver therapeutic payloads for the treatment of autoimmune and inflammatory disorders. Its lead program LFD-200, a subcutaneous glucocorticoid ADC, is in Phase 1 clinical trials for moderate-to-severe rheumatoid arthritis, and the company is building a broader pipeline using its ADC platform with diverse payloads such as ASOs and siRNAs.

Product overview

Lifordi Immunotherapeutics is a clinical-stage biotech company developing antibody-drug conjugates (ADCs) for autoimmune and inflammatory disorders. The core product is LFD-200, a glucocorticoid ADC currently in Phase 1 trials for rheumatoid arthritis. The company is building a broader pipeline leveraging its VISTA-targeting ADC platform to deliver diverse payloads including antisense oligonucleotides (ASOs) and siRNAs to immune cells. The platform enables targeted delivery of therapeutics to address unmet needs in rheumatology, gastroenterology, pulmonology, and dermatology.

Differentiator

Problem solved

Functional benefit

Products and services

• LFD-200 LFD-200 is an antibody-drug conjugate designed to deliver glucocorticoids directly to VISTA-expressing immune cells for treating autoimmune and inflammatory disorders. It features a short serum half-life (14 hours) with prolonged tissue exposure, subcutaneous formulation, and demonstrated efficacy in multiple preclinical disease models including rheumatoid arthritis. Currently in Phase 1 clinical trials.
• ASO ADC Pipeline Candidate An antisense oligonucleotide (ASO) ADC candidate that leverages Lifordi's VISTA-targeting ADC platform to deliver nucleic acid payloads to immune cells. Currently in lead optimization stage with demonstrated efficacy in multiple Th2-driven disease models.
• ADC-Based Delivery Platform A targeted delivery platform using antibody-drug conjugates to target VISTA-expressing immune cells. The platform enables delivery of diverse payloads including glucocorticoids, antisense oligonucleotides (ASOs), siRNAs, and small molecule inhibitors to innate and adaptive immune cells across multiple therapeutic areas including rheumatology, gastroenterology, pulmonology, and dermatology.

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Emerging players

• Kymera Therapeutics: Clinical-stage biotech developing targeted protein degradation (TPD) therapies for immunology and oncology indications, including autoimmune diseases. Comparable emerging autoimmune-focused biotech with similar clinical stage and platform-based pipeline strategy.
• Bolt Biotherapeutics: Clinical-stage immuno-oncology company developing immune-stimulating antibody-drug conjugates (ISACs) using a proprietary linker-payload platform. Adjacent peer through shared ADC platform technology and similar clinical-stage trajectory in targeted immunology.
• Pyxis Oncology: Clinical-stage ADC developer focused on immuno-oncology, with a flexible conjugation platform supporting diverse payloads. Comparable to Lifordi through shared ADC technology platform and pipeline-modular approach, though focused on oncology rather than autoimmune indications.
• Heidelberg Pharma: German clinical-stage biotech developing ADCs based on proprietary Amanitin payload technology, with emerging autoimmune and inflammatory applications. Comparable ADC platform developer with adjacent payload-modular strategy.
• Prometheus Biosciences: Clinical-stage precision immunology company (acquired by Merck in 2023 for ~$11B) that developed targeted therapies for immune-mediated diseases including IBD. Comparable as a successful autoimmune-platform biotech exit and competitive benchmark for valuation.

Direct peers

• Janux Therapeutics: Clinical-stage company developing T cell engager immunotherapies for cancer with emerging autoimmune applications using a proprietary TRIGGER platform. Comparable to Lifordi as a clinical-stage targeted-immunology platform company exploring indications beyond oncology.
• Q32 Bio: Clinical-stage immunology biotech developing targeted therapies modulating the IL-7 / TSLP pathway and complement system for autoimmune disease. Direct peer given shared autoimmune focus, similar clinical stage, and overlapping leadership pedigree (Lifordi's CEO chaired Q32 Bio's board).
• Dren Bio: Clinical-stage biotech developing antibody-based therapeutics for autoimmune and inflammatory diseases, with a focus on bispecific antibodies and targeted immune cell engagement. Direct peer to Lifordi in applying targeted biologics to chronic inflammatory indications.

Broad incumbents

• AbbVie: Global pharmaceutical leader with Humira/Skyrizi/Rinvoq dominating the autoimmune market that Lifordi ultimately targets. Relevant as the competitive incumbent Lifordi's platform must displace or differentiate against in rheumatology and gastroenterology.
• Sanofi: Global pharmaceutical company with a major autoimmune franchise (Dupixent) and the strategic investor in Lifordi via Sanofi Ventures. Comparable as both a potential acquirer and as a competitive incumbent in autoimmune and inflammatory disease therapeutics.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/lifordi-immunotherapeutics-inc

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds2 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lifordi Immunotherapeutics